Landmark Bill will strengthen patient access to new meds in Australia

2 December 2021
australia_big-1

Australians are expected to see improved access to new and innovative medicines, vaccines and treatments as a landmark Bill passes in Parliament today.

The recently legislated laws will ensure funding for new medicines in the Pharmaceutical Benefits Scheme (PBS), as well as several new initiatives that elevate Australian patients and their real-life experiences. Patients becoming more engaged in key decision-making processes is a progressive step forward that will benefit our whole health system. Involving more patients to share their real-world evidence will place a higher value on medicines and treatments that give patients better quality of life and improved health outcomes.

The new legislation formalizes elements of the five-year Strategic Agreement, which was signed by the Minister for Health and Aged Care, Greg Hunt MP, and trade group Medicines Australia in September this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical